Clinical trials: General Anxiety Disorder
Generalized Anxiety Disorder (GAD)
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- NCT06846320
- Testing
- ABBV-932, Antidepressant Therapy (ADT)
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- AbbVie
Anxiety Disorders
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time.
- Trial name
- NCT00543920
- Testing
- MK0777
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- GOLD (NCT00329446)
- Testing
- Quetiapine Fumarate, Escitalopram oxylate
- Where
- 63 sites in United States
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD
- Trial name
- BGFN-2022-02 (NCT06243640)
- Testing
- Buagafuran capsules, 15mg/ capsule, Buagafuran capsules mimic, 0mg/ capsule
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Anxiety Disorders
Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder
The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for individuals with generalized anxiety disorder.
- Trial name
- NCT03683472
- Testing
- Unwinding Anxiety Phone App
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- MindSciences, Inc.
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00390533
- Testing
- Saredutant
- Where
- 2 sites in United States, Australia
- Volunteers
- 428 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD.
- Trial name
- NCT07478744
- Testing
- SYT-510
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Synendos Therapeutics AG
Generalized Anxiety Disorder
Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder
The study will evaluate the long-term maintenance of efficacy of Lu AA21004 in patients with Generalized Anxiety Disorder (GAD) who responded to acute treatment with Lu AA21004.
- Trial name
- NCT00788034
- Testing
- Lu AA21004
- Where
- 81 sites in Argentina, Chile and 9 more
- Volunteers
- 459 people
- Sponsor
- H. Lundbeck A/S
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- TITANIUM (NCT00329264)
- Testing
- Quetiapine fumarate
- Where
- 58 sites in United States
- Volunteers
- 876 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per…
- Trial name
- NCT07759128
- Testing
- SEP-363856
- Where
- 17 sites in United States
- Volunteers
- 576 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Anxiety
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.
- Trial name
- NCT00151450
- Testing
- Pregabalin, Venlafaxine XR
- Where
- 45 sites in Belgium, Canada and 6 more
- Volunteers
- 390 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult…
- Trial name
- NCT07786454
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
The purpose of this study is to investigate the absorption, metabolism and excretion of [14C] PD 0332334 to characterize plasma, fecal and urinary radioactivity and identify any metabolites of [14C] PD 0332334.
- Trial name
- NCT00537615
- Testing
- PD 0332334
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to…
- Trial name
- ELECTRA (NCT00332891)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Croatia and 3 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Generalized Anxiety Disorder
Pilot Study of Virtual Reality for Providing Exposure Therapy to Children
Drs. from the Mayo Clinic Rochester will plan and execute a feasibility study of the phase I prototype version of the Virtual Reality exposure therapy system. Dr.
- Trial name
- NCT03208348
- Testing
- Pilot Virtual Reality
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old.
- Trial name
- NCT05729373
- Testing
- SEP-363856
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 434 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Insomnia, Generalized Anxiety Disorder
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder.
- Trial name
- NCT00235508
- Testing
- Eszopiclone (Lunesta)
- Where
- 64 sites in United States
- Volunteers
- 420 people
- Sponsor
- Sumitomo Pharma America, Inc.